In a Swedish national cohort of 95,490 patients with depression or anxiety receiving noninsulin antidiabetic therapy, within-individual analyses showed that semaglutide use was associated with a 42% lower risk of worsening mental illness compared with periods of nonuse, while liraglutide showed a smaller reduction and exenatide and dulaglutide showed no association. Semaglutide was also associated with lower risk of worsening depression, anxiety, substance use disorder, and self-harm, with consistent findings across sensitivity analyses, although causality could not be established due to the observational design.

Source: The Lancet Psychiatry